Adverem Biotechnologies: Gene Therapy Company And Our New Buy – Seeking Alpha
Seeking Alpha |
Adverem Biotechnologies: Gene Therapy Company And Our New Buy
Seeking Alpha We bought shares of Adverem Biotechnologies (ADVM). The stock is at an attractive entry point ahead of phase I/II data from a gene therapy trial in alpha-1 antitrypsin deficiency in the second half of this year. We are rating the stock a Buy with price … Adverum Biotechnologies Inc. (ADVM) Plunges 6.03% on April 06Equities.com Analysts’ Weekly Ratings Changes for Adverum Biotechnologies (ADVM)Week Herald Adverum Biotechnologies (NASDAQ:ADVM) Downgraded to Hold at Zacks Investment ResearchStockNewsTimes |
Seeking Alpha |
Adverum Biotechnologies: Gene Therapy Company And Our New …
Seeking Alpha The stock is at an attractive entry point ahead of phase I/II data from a gene therapy trial in alpha-1 antitrypsin deficiency in the second half of this year. We are rating the stock a Buy with price target = $18. We bought shares of Adverum … Adverum Biotechnologies, Inc. (ADVM) Declined to $5.45 on Apr, 8Houston Style On Fleek What’s Adverum Biotechnologies, Inc. (ADVM) Downside After Today’s Significant Decline?NMSU Herald Zacks Premium Investment Service – Zacks.comZacks |